麻豆传媒

Dr Permal Deo has a background in Molecular Biology with a focus on advanced glycation endproducts (AGEs), and food safety. His Masters was obtained from The University of Queensland, Australia where his research focused on food mycotoxins.  He graduated with a PhD from Queen’s University-Belfast, UK, where he researched on the role of advanced glycation endproducts on AGE-receptors, NF-kB, and pro-inflammatory cytokines. He joined the University of South Australia in 2010, after working at The University of the South Pacific, Fiji Islands. He is also a Visiting Scientist at CSIRO focusing on the molecular mechanism linking diabetes and Alzheimer’s disease.
Dr Deo’s research focuses on AGE-induced receptors (RAGE), and activation of downstream signalling mechanisms including MAP kinase and NF-kB pathways. The impact of AGE on cell cytotoxicity, DNA –damage, and on Telomere dynamics are also explored.  His research examines the role of natural products on AGE-induced signaling cascade as an alternative therapeutic approach. The role of these products with high antioxidant activities and/or their potential anti-inflammatory activities enables better insight on the mechanism in preventing or delaying the onset of chronic diseases. One of his interests is to study the role and functions of Australian Medicinal and Native Food plants in these signaling cascades.
From food safety perspective, his research focuses on antimicrobial properties of plant based novel peptides. The research also examines microbial analysis using molecular techniques of food and environmental samples.

Research units
Research expertise



Obesity, prediabetes and type 2 diabetes
Lipoprotein metabolism
Physiology of white adipose tissue
Nutritional interventions
Human studies

Our clinical and fundamental research studies novel mechanisms that may lead to the development of cardiometabolic diseases in humans, such as type 2 diabetes and atherosclerosis. More particularly, we study the role of atherogenic lipoproteins and dysfunctional adipose tissue in this process. Furthermore, we examine the effect of various nutritional interventions as therapeutic tools that could reverse early cardiometabolic abnormalities. These projects will contribute to the prevention of type 2 diabetes in humans, particularly in subjects with obesity.


 Member



 

Adjunct professor, Division of Experimental Medicine, Faculty of Medicine, McGill University
Researcher, Montreal Diabetes Research Center (CRDM)




Professional titles and affiliations

Titles: corporations and professional organizations


Member, Order of Dietitians-Nutritionists of Quebec (ODNQ)


Disciplines

Clinical Sciences
Endocrinology and Metabolism
Nutrition
Biochemistry
Medical Biochemistry
Physiology



Areas of expertise

Obesity
Diabetes
Metabolism
Metabolic Disorders
Metabolic Diseases
Physiology
Nutritional Disorders
Nutrition
Atherosclerosis
Tassels and Fabrics
Lipid Disorders
Menopause
Age and Risk Factors
Cardiovascular Diseases
Health Prevention
Health Promotion
Americas
Canada (Quebec)
2000 AD - Present

Dr Jennifer M. Yeh is a decision scientist whose research focuses on improving health outcomes at the population level. She is an Assistant Professor of Pediatrics at Harvard Medical School and Boston Children’s Hospital. Dr Yeh has an M.S. in Health Policy and Management from the Harvard T.H. Chan School of Public Health and a PhD in Health Policy from Harvard University. She has extensive experience applying decision-analytic modelling and cost-effectiveness analysis methods to evaluate clinical guidelines and inform health policy. Her research identifies opportunities to improve cancer control efforts spanning across the cancer continuum from prevention to survivorship. She is funded by the National Cancer Institute (NCI), the National Institute of Child Health and Human Development (NICHHD), and the American Cancer Society (ACS).

---

Wade Van Horn is an assistant professor in the School of Molecular Sciences and is an investigator with the Biodesign Institute's Center for Personalized Diagnostics, and the Magnetic Resonance Research Center. He joined Arizona State University in 2012 after an American Heart Association postdoctoral fellowship at Vanderbilt University School of Medicine in the Department of Biochemistry and the Center for Structural Biology. He received his Ph.D. from the University of Utah's Department of Chemistry. His current interests focus on the interplay between biomolecular function and structure, especially as it relates to human physiology and pathophysiology.



Education

Ph.D. Chemistry, University of Utah 2007

Dr. Mehmood Khan’s distinguished career has included several senior corporate roles, including Vice Chairman and Chief Scientific Officer of Global Research and Development at PepsiCo, and President of Global R&D at Takeda Pharmaceuticals.
Before moving into the private sector Dr. Khan was a faculty member in endocrinology at the Mayo Clinic and Medical School, where he served as Director of the Diabetes, Endocrine and Nutritional Trials Unit. He also led programs in diabetes, endocrinology, metabolism, and nutrition in Minneapolis.
Dr. Khan is a member of the Board of Directors of Reckitt Benckiser and of the Saudi Research, Development, and Innovation Authority (RDIA), Executive Chairman of Life Biosciences, a member of the Saudi National Biotechnology Strategy Steering Committee, and Chairman of the Visiting Committee on Advanced Technology of the United States’ National Institute of Standards and Technology (NIST).
Dr. Khan earned his medical degree from the University of Liverpool School of Medicine, England, and completed a fellowship in clinical endocrinology and nutrition in the Department of Medicine and Food Science and Nutrition at the University of Minnesota, Minneapolis. He is a Fellow of the Royal College of Physicians in London, a Fellow of the American College of Endocrinology, and an Elected Fellow in the Department of Pharmacology at University of Oxford.

Obesity medicine physician Eleanor Yusupov, D.O., serves as an assistant professor at New York Institute of Technology's College of Osteopathic Medicine (NYITCOM). Specializing in internal medicine, she is certified by the American Board of Internal Medicine and American Board of Obesity Medicine. She practices primary care at NYITCOM's healthcare centers in Old Westbury and Central Islip (both in New York).
Prior to joining the medical school's faculty, Yusupov practiced hospital medicine in leading academic medical centers, where she specialized in graduate medical education, acute inpatient care, and medical consultation.
Yusupov earned her D.O. degree from NYITCOM and also holds a Master of Public Health degree from Stony Brook University.

Professor Alisa Phulukdaree's work takes place at the basic molecular and cellular levels, which evaluates how genetic differences influence the risk of getting type 2 diabetes and heart disease between ethnic groups including people of Caucasian, African and Indian descent. These findings impact society by creating an awareness of the differences that exist. Thus by educating society, they can make informed decisions in their lifestyle choices.
Her teaching responsibilities include knowledge dissemination in medical biochemistry and molecular mechanisms of disease at undergraduate, postgraduate and postdoctoral levels.